• 18th Meet The Professor. Advanced International Breast Cancer Course (AIBCC)

    Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.
    As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more.
    New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, tio allow for a rational de-escalation or escalation of  curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.
    The 18th AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.

    FELLOWSHIPS
    Some fellowship will be awarded including registration and 2 Hotel nights. Those interested should send a short CV and a motivation letter within
    October 10th to info.bologna@accmed.org. The organizing secretariat will confirm the fellowship within October 20th and proceed with the organization of logistics. 

    UNDER 40
    Accademia will provide a limited amount of free registrations for Physicians, Biologists, Pharmacists and Nurses “Under 40”. Those interested should send
    email within October 10th to info.bologna@accmed.org. The organizing secretariat will confirm the registration by email. 

    Pierfranco Conte, Scientific Lead, presents AIBCC 2022 

  • How to participate the meeting

    To encourage participation, this event will take place in a hybrid form. It will be possible to follow the activity at the congress venue or remotely.

    The two buttons below allow you to register according to the desired method, as long as available places are available. Enrollment in the course can only be done through the online procedure, no new registrations will be accepted at the congress venue.

    Go to the Residential Course - Padua

    Go to the Digital Event - ONLINE              

    Participants who will follow the activity remotely will need a stable and fast internet connection and a device (PC, Smartphone, Tablet) with a recent internet browser (i.e. any updated version of Chrome or Firefox).

  • Programme

    10.15Introduction to the ConferencePierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat
    SESSION I – EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGY: IMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION
    Chairpersons: Hesham Ahmed Gaballah Elghazaly,  Aleix Prat
    10.30Biological heterogeneity and clinical outcomes in HR+/HER2-negative diseaseMaria Vittoria Dieci
    11.00PDL1, TMB, TROP2, immune infiltration and genomic classifiers in TNBCGiampaolo Bianchini
    11.30Is HER2-low breast cancer a real entity? Scoring issues and biological heterogeneityGiuseppe Viale
    12.00HER2+ early breast cancer: potential role of genomic classifiersAleix Prat
    12.30

    Q&A

    13.00Lunch
    SESSION II – CHANGING PARADIGMS FOR LOCOREGIONAL TREATMENTS MASTECTOMY, BREAST RECONSTRUCTION AND RADIATION THERAPY
    Chairpersons: Jaceck Jassem, Philip Poortman
    14.00When is breast-conserving therapy really not avoidableOreste Davide Gentilini
    14.30Breast reconstruction: when and how?Vincenzo Vindigni
    15.00Radiation therapy after breast reconstructionOrit Kaidar-person
    15.30

    Q&A

    Multidisciplinary Tumor Board 1 – Locoregional treatment
    Panelists: Bettina Borisch, Oreste Gentilini, Jacek Jassem, Eleftherios Mamounas, Orit Kaidar-Person, Philip Poortmans, Fedro Peccatori
    16.00Clinical case 1. Second breast conserving therapyTania Saibene
    16.15Clinical case 2. Patient with lymph node seen on planning CT-scan: what now? (RT)Silvia Michieletto
    16.30Clinical case 3: BOOP: after or due to radiation therapyLuca Visani
    16.45Concluding commentsEleftherios Mamounas, Fedro Alessandro Peccatori
    17.00

    Adjourn

    17.45Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2022
    18.00Lecture of the Awardee
    18.30

    Cocktail

    19.30

    Adjourn

    The Ceremony and the cocktail will take place in Palazzo Bo, Via VIII Febbraio 2, Padova

    SESSION III – EARLY BREAST CANCER. FINE TUNING FROM DE-ESCALATION TO ESCALATION
    Chairpersons: Pierfranco Conte, Miguel Martin
    9.00Tailoring neoadjuvant/adjuvant treatment for triple negative breast cancerSibylle Loibl
    9.30Risk adapted treatment of early HR+/HER2- breast cancer: from modulation of endocrine treatment to novel agentsStephen Johnston
    10.00Is there a role for anthracyclines in contemporary treatment of early breast cancer?Valentina Guarneri
    10.30

    Q&A

    11.00Coffee Break
    Multidisciplinary Tumor Board 2 - Early breast cancer
    Panelists: Bettina Borisch, Pierfranco Conte, Valentina Guarneri, Jacek Jassem, Stephen Johnston, Sibylle Loibl, Miguel Martin, Fedro Peccatori
    11.30Clinical case 1. Node positive, premenopausal patient: role of genomic classifiersCristina Falci
    11.45Clinical case 2. HR+HER2+ patient with residual disease after neoadjuvant therapyFederica Miglietta
    12.00Clinical case 3. Adjuvant treatment in rare histologiesGrazia Vernaci
    12.15Concluding commentsJacek Jassem, Miguel Martin
    12.30Lunch
    SESSION IV – METASTATIC BREAST CANCER: NEW OPTIONS, NEW ALGORITHMS
    Chairpersons: Bettina Borisch, Alessandra Gennari
    13.30HER2+ advanced breast cancer: new treatment algorithmsSandra Swain M
    14.00TN advanced breast cancer: biology-driven treatment algorithmsHope Rugo
    14.30HR+ advanced breast cancer: what after CDK4/6?Giuseppe Curigliano
    15.00

    Q&A

    Multidisciplinary Tumor Board 3 – Metastatic Breast Cancer
    Panelists: Bettina Borisch, Pierfranco Conte, Giuseppe Curigliano, Hesham Ahmed Gaballah Elghazaly, Hope Rugo, Sandra Swain
    15.30Clinical case 1. Brain metastasesGaia Griguolo
    15.45Clinical case 2. Possibility of discontinuing treatment in very long term respondersCarlo Alberto Giorgi
    16.00Clinical case 3. Locoregional treatment for oligometastatic disease or role of NGS in ABCMichele Bottosso
    16.15Concluding commentsPierfranco Conte, Hesham Ahmed Gaballah Elghazaly
    16.30

    Take home messages and adjourn